VistaGen Therapeutics Inc. (VTGN): Detailed Summary on Healthcare Stock

0
42

VistaGen Therapeutics Inc. (NASDAQ:VTGN) changes shares on Thursday trading session, with a change of -6.91% or -$0.04 shares. The trading starts at $0.5599 and closed at $0.55 throughout the day. The trading session low price was $0.505 and day high was $0.56 on Thursday, June 18. After the session, the Healthcare sector daily volume shifted to 0.81 million while its average volume is 799.95K. In other hand, the VTGN market cap reached to $23.08M. While, its current target price is $0.51 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 5.52% and up 3.43% for month. Its quarterly performance was 38.38% above, while its half year performance is down -43.43%. VTGN yearly performance stood at negative -34.29% and fall -25.76% for year-to-date. Current recommendation for VistaGen Therapeutics Inc. is 2.50.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. VTGN EPS (TTM) for 12-month is -0.60. EPS for this year is 19.70%, while for the next year its value is -0.35. Its EPS Q/Q reached 40.50%. It has an EPS of 19.70% up for past five years.

Let’s take a look on the analyst recommendations on VTGN for the current month and previous month. For the current month, 1 of 2 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $1.00-$1.00. Average target price for VTGN was reached at $1.00.

The insider ownership moved to 10.27% and institutional holding shifted to 13.20%.

The company posted an EPS (TTM) of -0.60. According to the most recent quarter report on (Mar 2020), 2 analysts estimated an average EPS of -0.08, while -0.17 EPS posted a year ago period. Analyst Estimated EPS for VTGN published in the report was -0.1–0.06 during the same period. Comparing with last year, the average estimated EPS was -0.17 which is lower than -0.15 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for VTGN fall -25.23% for period of 200 days. SMA for 50 days was 14.27% which is showing green signal, while SMA-20 was 5.06%. The moving average value for VistaGen Therapeutics Inc. (VTGN) is 0.5518 and 0.4571 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in VTGN stock. On Nov 20, SNODGRASS H. RALPH, PRES./CHIEF SCIENTIFIC OFFICER, bought 15,000 trading shares at the cost of $0.34, which valued at 5100.0.